Document text
Principal Investigator: Iain Fraser
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2020
Award: $12,723
Funding agency: National Institute of Allergy and Infectious Diseases
Cells of the innate immune system, such as dendritic cells and macrophages, constantly patrol host mucosal surfaces and peripheral tissues for signs of infection or injury. Since many people infected with SARS-CoV-2 clear the virus without developing symptoms, aspects of the innate immune response may hold the key to defeating this virus. The potential for an adverse cytokine storm depends on the interaction of different cell types at the site of infection. This highlights the need to study the immune response to SARS-CoV-2 in a combined environment of both epithelial cells, which are the primary target of infection, and innate immune cells such as macrophages, which are crucial drivers of inflammation.
Since this project has only recently started, we will primarily summarize the future research plan. We propose to first establish a co-culture assay which can measure both viral replication in Calu3 human epithelial cells, an established CoV-2-permissive line, and IL-6 expression from THP1 human macrophages. As both assay readouts will be FACS-based, this will permit used of a pooled CRISPR screening approach, which will be less labor intensive on a genome-wide scale and more feasible with available equipment in the NIAID BSL-3 lab.
Post-infection, we will sort CD32+ THP1 cells from CD324+ (E-cadherin) Calu3 cells, and assay the cells for viral levels and IL-6 expression. Viral levels will be assayed using a recently developed mNeonGreen fluorescent reporter virus which we have received from UTMB, while IL-6 will be assayed by well-established lab protocols for intracellular cytokine staining. Our expectation is that the Calu3 cells will be the primary target for CoV-2 infection, and THP1 the primary IL-6 producers. For this reason, we initially seek to identify regulators of IL-6 in THP1 cells, while limiting the study of host factors of SARS-CoV-2 infectivity to Calu3 cells. As soon as the BSL-3 lab in the main campus is available to us for SARS-CoV-2 research, we will establish the viral infection and IL-6 expression assays as FACS-based readouts, and establish the reproducibility of the screen assays with positive control genes targeted by specific CRISPR/Cas9 gRNAs. We expect the confirmed human receptor for CoV-2, ACE2, to be an appropriate positive control for viral infection and possibly also for the IL-6 response. We will optimize the viral infection time, multiplicity of infection (MOI), incubation period for golgi block, cell fixation, IL-6 staining conditions and FACS-sorting for both fluorescent virus infection levels and IL-6 expression.
Once the primary assay is established, we propose to use an NCATS-provided CRISPR-based lentiviral library in pooled format (Cellecta). THP1 cells and Calu3 cells will be separately infected with lentivirus and drug-selected under BSL-2 conditions. To ensure an average of 1 gRNA per cell, we will use an MOI of 0.3 for the lentiviral infection. Control pools of lentivirus-infected THP1 and Calu3 cells will be retained for the later sequencing step to identify gRNAs that are lost from the library pool due to effects on cell viability.
SARS-CoV-2 preparation and infection will be performed in the BSL-3 lab. As described earlier, we will screen Calu3 cells and differentiated THP1 cells in a co-culture system by mixing the CRISPR library-infected cells in a 1:1 ratio. After infection with SARS-CoV-2, cells will be treated with golgi block, fixed with 4% PFA and stained for IL-6, CD32 and CD324 following the previously optimized protocols. We will follow standard operating procedures for BSL-3 CoV-2 work to permit the fixed cells to be FACS-sorted under BSL-2 conditions.
Assuming that Calu3 cells are the primary viral target and THP1 the primary IL-6 producers, we will sort six populations of cells: Highest and lowest 20% of THP1 cells stained for IL-6 expression and intermediate 60% of IL-6 stained cells as control, and highest and lowest 20% of Calu3 cells analyzed for viral fluorescence also with intermediate 60% of cells as control. Genomic DNA will be isolated, gRNA sequences amplified by PCR and deep sequencing will be used to identify gRNAs that are enriched in the high/low 20% sets compared to the intermediate 60%. We will repeat the screen in triplicate to identify gRNAs that appear consistently in the high/low 20% populations. Genes targeted by these gRNAs will be followed up as candidate hits.
In FY2020, we have conducted pilot assays under BSL-2 conditions with the human coronavirus OC43. We have confirmed we can effectively FACS-separate the epithelial cells and macrophages after co-culture and viral infection, and are currently evaluating whether this system drives a strong macrophage IL-6 response.
Terms: <2019 novel coronavirus><2019-nCoV><Active Follow-up><Assay><B cell differentiation factor><B cell stimulating factor 2><B-Cell Differentiation Factor><B-Cell Differentiation Factor-2><B-Cell Stimulatory Factor-2><BCDF><BSF-2><BSF2><Bioassay><Biologic Assays><Biological Assay><Blood monocyte><Body Tissues><CD 32 Antigens><CD32><CD32 Antigens><COVID-19><COVID-19 epidemic><COVID-19 pandemic><COVID19><COVID19 epidemic><COVID19 pandemic><CRISPR><CRISPR editing screen><CRISPR library><CRISPR method><CRISPR methodology><CRISPR screen><CRISPR technique><CRISPR technology><CRISPR-CAS-9><CRISPR-based library><CRISPR-based method><CRISPR-based screen><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/Cas method><CRISPR/Cas system><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 library><CRISPR/Cas9 screen><CRISPR/Cas9 technology><Cadherin-1><Cas nuclease technology><Cell Body><Cell Death><Cell Differentiation><Cell Differentiation process><Cell Line><Cell Survival><Cell Viability><CellLine><Cells><Cellular Assay><Cessation of life><Clustered Regularly Interspaced Short Palindromic Repeats><Clustered Regularly Interspaced Short Palindromic Repeats library><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Co-culture><CoV emergence><Cocultivation><Coculture><Coculture Techniques><Death><Dendritic Cells><Disease><Disorder><Drugs><E-Cadherin><Ensure><Environment><Epithelial><Epithelial Calcium-Dependent Adhesion Protein><Epithelial Cells><Epithelial-Cadherin><Epithelium><Epithelium Part><Equipment><Extracellular Space><Fc gamma RII><Fluorescence><Gene Targeting><Genes><Genetic Screening><Genomic DNA><Goals><Golgi><Golgi Apparatus><Golgi Complex><Guide RNA><HCoV><HPGF><Hepatocyte-Stimulating Factor><Host Factor><Host Factor Protein><Human><Hybridoma Growth Factor><IFN-beta 2><IFNB2><IL-6><IL6 Protein><Immune><Immune response><Immunes><Immunological response><Infection><Inflammation><Inflammatory><Inflammatory Response><Injury><Innate Immune Response><Innate Immune System><Integration Host Factors><Intercellular Space><Interleukin-6><Lentivirinae><Lentivirus><Libraries><Lung><Lung Respiratory System><MGI-2><Marrow monocyte><Measures><Medication><Modern Man><Mucosa><Mucosal Tissue><Mucous Membrane><Myeloid Differentiation-Inducing Protein><NIAID><National Institute of Allergy and Infectious Disease><Patients><Peripheral><Pharmaceutic Preparations><Pharmaceutical Preparations><Phenotype><Plasmacytoma Growth Factor><Population><Preparation><Procedures><Protocol><Protocols documentation><Receptor Protein><Reporter><Reproducibility><Research><SARS-CoV-2><SARS-CoV2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Sampling><Severe acute respiratory syndrome coronavirus 2><Site><Sorting - Cell Movement><Staining method><Stains><Strains Cell Lines><Subfamily lentivirinae><Surface><Symptoms><System><Time><Tissues><Uvomorulin><Veiled Cells><Viral><Viral Diseases><Virion><Virus><Virus Diseases><Virus Particle><Virus Replication><Virus-Lenti><Work><Wuhan coronavirus><active followup><adverse consequence><adverse outcome><base><cell assay><cell fixation><cell type><clustered regularly interspaced short palindromic repeats screen><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019><coronavirus disease 2019 epidemic><coronavirus disease 2019 pandemic><coronavirus emergence><cultured cell line><cytokine><cytokine release syndrome><cytokine storm><deep sequencing><drug/agent><emergent CoV><emergent coronavirus><emerging CoV><emerging coronavirus><expectation><follow up><follow-up><followed up><followup><gDNA><gRNA><genome scale><genome-wide><genomewide><host response><human CoV><human corona virus><human coronavirus><immunoresponse><injuries><interferon beta 2><macrophage><monocyte><nCoV><necrocytosis><new CoV><new coronavirus><novel CoV><novel coronavirus><pulmonary><receptor><recruit><response><screening><sorting><therapeutic target><viral infection><viral multiplication><viral replication><virus infection><virus multiplication><virus-induced disease>